Advancing Molecular Diagnostics to Personalize Cancer Therapy

Date: June 22, 2011
Pages: 187
Price:
US$ 3,835.00
Publisher: Business Insights
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AA4C7C6562CEN
Leaflet:

Download PDF Leaflet

Advancing Molecular Diagnostics to Personalize Cancer Therapy
Introduction

This report analyzes current and potential world markets for key cancer-based molecular diagnostics, including advances in the field. This report forecasts future growth to 2016. Market segments covered include: breast cancer; colon cancer; prostate cancer; non-small cell lung cancer; melanoma; and renal cancer. This report reviews the direction of research, and key issues facing the industry.

Features and benefits
  • Identify key innovations in molecular diagnostics for oncology that may compete with those in development at your company.
  • Understand the regulatory challenges facing the developers of molecular diagnostics for cancer.
  • Understand the challenges that surround successfully commercializing a combined drug-diagnostic product and learn how to overcome them.
  • Discover and analyze the key technology platforms being used in the development of novel molecular diagnostics.
  • Discover the forecast market size for key segments of the cancer diagnostics market including: breast, colorectal, prostate, lung, and renal cancer.

Highlights

Advances in genomics, proteomics, molecular imaging, and other new technologies are leading to a molecularly based reclassification of malignancy, creating market opportunities for diagnostic companies.

Companion diagnostics - linking drugs with diagnostics - is expected to become the prevailing health care model, offering advantages for both the prescription drug and diagnostics businesses. For diagnostics companies, combining with a successful companion drug can be a powerful driver of sales, especially when required for prescribing a drug.

If government regulatory agencies increase the use of biomarkers and diagnostics in prescribing decisions, it is likely that drug and diagnostics companies will increase their collaboration. New relationships are likely to develop between partners committed to personalized medicine embracing the approach of specialized pharmaceutical firms.

Your key questions answered
  • Which of the cancer diagnostic market segments are forecast to grow most rapidly through to 2016 and thus be the most commercially attractive?
  • What are the key innovations in molecular diagnostics that are going to drive market growth?
  • How can pharma and diagnostic companies work together to successfully develop combined drug and diagnostic products?
  • Which companies are developing the most promising technologies?
EXECUTIVE SUMMARY

Introduction
Trends in cancer diagnostics
Market developments
Market analysis

ABOUT THE AUTHOR

Disclaimer

INTRODUCTION

Summary
Perspective
  Growing global incidence of cancer
  The impact of unhealthy lifestyles on cancer
  Personalized therapy gets closer
Molecularly targeted therapeutics
  Move toward rationally designed trials
  Accelerate the translation of preclinical research
Strategies toward personal cancer treatment
Near-term market opportunities
  New pharmacogenomics, panels and arrays
  Driving demand for tests
Drug-diagnostic co-development
  Targeted drugs fueling diagnostic growth
  Stratifying patients to the best treatment

TRENDS IN CANCER DIAGNOSTICS

Summary
An evolving science
  Demonstrating value
Evolving health care practices
  Reducing time to market
  Addressing regulatory concerns
  Changing clinical practice
Diagnostic influences therapeutic molecule discovery
  Identifying patient populations
Key platforms

  PCR

  Nucleic acid testing
  Microfluidics
  Gene expression profiling
  Variety
The role of biomarkers
  Prognostic
  Predictive
  Evaluating therapeutic activity
Challenges and issues
  Commercializing theranostics
  Regulatory challenges
  Technical challenges
  DTCs and CTCs

MARKET DEVELOPMENTS

Summary
New molecular test for cervical cancer
  Detecting high risk types of HPV
License for EGFR lung cancer assay
Licensing agreement extended for prostate cancer biomarker
bioMérieux, GSK develop theranostic for treatment selection
Diagnostic test for pancreatic cancer
Test to select candidates for skin cancer immunotherapy
Collaboration for therapy, companion diagnostic
Companion diagnostics collaboration
Deal to accelerate development of new cancer diagnosis tools
Biomarkers for personalizing radiation cancer treatment
CTC antibodies on a chip track mesothelioma
Body fluid based oncology diagnostics
Highly validated genetic markers for malignant melanoma
Biomarkers for DNA methylation on melanoma tissue
Diagnostic predicts prostate cancer recurrence
Colorectal cancer test approved

MARKET ANALYSIS

Summary
Market drivers
  Improving on prescription by trial and error
  A need for more rapid, specific testing
Opportunities
  Drug-diagnostic combinations
  Rescuing failed drugs
  An unmet need for improving diagnosis
Selected novel products on the market
  HPV and cervical cancer
  Multigene expression testing
  Predicting risk of recurrence
  Gene overexpression
  KRAS mutations
  Molecular classification
  Mutation analysis
  Drug resistance testing
  Measuring exposure to drugs
World market analysis
  Total solutions
  Drug labeling modifications
  Breast cancer
  Colorectal cancer
  Prostate cancer
  Non-small cell lung cancer
  Melanoma
  Renal cancer
  Market by type of diagnostic

CORPORATE PROFILES

Abbott Molecular
  Company description
Agendia
  Company description
Allegro Diagnostics
  Company description
Almac Group
  Company description
AltheaDx
  Company description
Asuragen
  Company description
Atossa Genetics
  Company description
AutoGenomics
  Company description
Becton, Dickinson and Company
  Company description
Biocartis SA
  Company description
bioMérieux SA
  Company description
Caris Life Sciences
  Company description
CCC Diagnostics LLC
  Company description
Cytocell Ltd.
  Company description
Dako Denmark
  Company description
deCODE genetics
  Company description
Epigenomics AG
  Company description
Exosome Diagnostics
  Company description
Foundation Medicine
  Company description
GE Healthcare
  Company description
Gene Express
  Company description
Genomic Health
  Company description
Gen-Probe
  Company description
Illumina
  Company description
IncellDx
  Company description
Innogenetics NV
  Company description
InterGenetics
  Company description
Ipsogen
  Company description
Kreatech Diagnostics
  Company description
MDxHealth
  Company description
Myriad Genetics
  Company description
Nanosphere
  Company description
Oncohealth
  Company description
On-Q-ity
  Company description
Orion Genomics
  Company description
Pathwork Diagnostics
  Company description
Predictive Biosciences
  Company description
Prometheus Laboratories
  Company description
Qiagen
  Company description
QuantaLife
  Company description
Roche Molecular Diagnostics
  Company description
Rosetta Genomics
  Company description
Transgene
  Company description
TrimGen
  Company description
TrovaGene
  Company description
Veridex
  Company description

APPENDIX

Scope
Methodology
Glossary/Abbreviations
Bibliography/References
Skip to top


Ask Your Question

Advancing Molecular Diagnostics to Personalize Cancer Therapy
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: